

Disclosures

Personal Commercial (42)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------------|---------------------------|--------------------------|---|
| <i>Self</i> | | | |
| Abiome | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Prevention</i> |
| Alnylam | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Alnylam | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Amgen | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Amgen | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Astra Zeneca | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Astra Zeneca | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Bayer | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies General Cardiology</i> |
| Bayer Healthcare Pharmaceuticals | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| BMS | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| BMS | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Boston Scientific | Research/Research Grants | Significant (>= \$5,000) | <i>Arrhythmias and Clinical EP</i> |
| Cardiac Dimensions | Consultant Fees/Honoraria | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Cardior | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Cardurion | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Celledon | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Corvia | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Cytokinetics | Research/Research Grants | Significant (>= \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Cytokinetics | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Heart Failure and Cardiomyopathies</i> |
| Eidos | Research/Research Grants | Significant (>= \$5,000) | <i>Congenital Heart Disease and Pediatric Cardiology Heart Failure and Cardiomyopathies</i> |

| | | | |
|------------------------------|------------------------------|--------------------------|--|
| Gilead | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Gilead Sciences, Inc. | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| GSK | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| GSK | Data Safety Monitoring Board | Modest (< \$5,000) | General Cardiology |
| Ionis | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Ironwood | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Janssen Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Merck | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Mesoblast | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Myokardia | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Myokardia | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| Quantum Genomics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Roche | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Sanofi | Research/Research Grants | Significant (>= \$5,000) | General Cardiology Prevention |
| Takeda | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Tenaya | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| TEVA/Mesoblast | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Theracos | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Theracos | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Theracos | Data Safety Monitoring Board | Significant (>= \$5,000) | General Cardiology |

Personal Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

Agreement

Certified Education Attestation | Signed on 2/8/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/8/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 2/8/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 2/8/2019

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.